CPHI [CHINA PHARMAS,] PRE 14C: (Original Filing)
[]
[SCHEDULE 14C INFORMATION Check the appropriate box: [X] Preliminary Information Statement [] [] Definitive Information Statement [Missing Graphic Reference] Payment of Filing Fee (Check the appropriate box): [X] No fee required. [] Feemputed on table below per Exchange Act Rules 14c-5(g) and 0-11. 1) Title of each class of securities to which transaction applies:]
[Page 3 4 EX-99.1 Press Release]
[TABLE OF CONTENTS EX-1.2] [DESWELL INDUSTRIES, INC. CERTIFIED TRUE COPY OF RESOLUTION AMENDMENT OF REGULATION 6.15 l. It was noted that in order to change the quorum requirements for meetings of the members of the Company, it was proposed that the first sentence of Regulation 6.15 of the Companys Articles of Association be deleted in its entirety and the following be substituted in its]
[FORM 10-K x For the fiscal year ended December 31, 2009 OR o to For the transition period from 333-147363 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-5101287 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province The People’s Republic of China 712046 (Zip Code) 011-86-29-33686638 o þ þ o o þ] [Wu Quan Mountain Land Use Transfer Agreement Party A: Village Committee of the Wu Quan Village, Jiang Cun Town, Hu County (Transferor) Party B: Shaanxi Aoxing Pharmaceutical Co., Ltd. (Transferee) I. Party A shall transfer the land use right to Party B of a land sized 9,000 Mou, east border at the center of Shi He, west border at the] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ronghua Wang, certify that: 1. I have reviewed this annual report on Form 10-K of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Elaine Zhao, certify that: 1. I have reviewed this annual report on Form 10-K of Biostar Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Ronghua Wang Chief Executive Officer March 31, 2010 EX-32.1 5 ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Elaine Zhao Chief Financial Officer March 31, 2010 EX-32.2 6 ex32-2.htm]
[FORM 10-K For the fiscal year ended December 31, 2009 OR For the transition period from ________________ to ________________ 001-15643 SKYSTAR BIO-PHARMACEUTICAL COMPANY Nevada 33-0901534 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China N/A (Zip Code) (8629) 8819-3188 Title of] [SERVICES AGREEMENT This SERVICES AGREEMENT (this “Agreement”), dated as of March 30, 2010, by and between Skystar Bio-Pharmaceutical Company, a Nevada corporation (the “Company”), and R. Scott Cramer, an individual, whose address is 1012 Lewis Drive Winter Park, Florida 32789-2225 (“Consultant”). The Company and the Consultant are collectively referred to herein as the “Parties.” RECITALS: A. B. NOW, THEREFORE, in] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bennet P. Tchaikovsky, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer March 31, 2010 EX-32.1 9 v179475_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer March 31, 2010 EX-32.2 10 v179475_ex32-2.htm] [Contract Registration No. 20096101021102 Technical Cooperation Agreement Name of Project: Cooperative Research of Party A: Xian Tianxing Bio-Pharmaceutical Co., Ltd. (stamp) Party B: Fourth Military Medical University (stamp) China Place of Execution: Xi’an, Shaanxi Province, China Date of Effective: September 23, 2009 Term of Validity: From September 23, 2009 to the date when the performances under the terms of the]
[EVER-GLORY INTERNATIONAL GROUP, INC. FORM 10-K For the Year Ended December 31, 2009 TABLE OF CONTENTS Part I 4] [SUBSIDIARIES Perfect Dream Limited, a corporation established under the laws of the British Virgin Islands Goldenway Nanjing Garments Co., Ltd, a wholly foreign-owned limited liability company formed under the laws of the People's Republic of China Nanjing Catch-Luck Garments Co., Ltd., a wholly foreign-owned limited liability company formed under the laws of the People’s Republic of China Nanjing New-Tailun Garments] [Section 302 of the Sarbanes-Oxley Act of 2002 I, Edward Yihua Kang, certify that: 1. I have reviewed this annual report on Form 10-K of Ever-Glory International Group, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in] [Section 302 of the Sarbanes-Oxley Act of 2002 I, Yan Guo, certify that: 1. I have reviewed this annual report on Form 10-K of Ever-Glory International Group, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Edward Yihua Kang Edward Yihua Kang Chief Executive Officer EX-32.1 6 v179237_ex32-1.htm] [OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Yan Guo Yan Guo Chief Finance Officer (Principal Finance Officer) EX-32.2 7 v179237_ex32-2.htm]
[March 31, 2010 Orient Paper, Inc. Nansan Gongli, Nanhuan Road Xushui County, Baoding City Hebei Province, The People’s Republic of China 072550 Ladies and Gentlemen: Company Initial Shares Common Stock Option Shares Shares Underwriting Agreement Underwriter Registration Statement SEC We are acting as counsel for Orient Paper, Inc., a Nevada corporation (the “ Subject to the limitations set forth below,] [3,000,000 Shares ORIENT PAPER, INC. Common Stock PURCHASE AGREEMENT March 31, 2010 ROTH CAPITAL PARTNERS, LLC 24 Corporate Plaza Drive Newport Beach, CA 92660 Ladies and Gentlemen: “Company” “Underwriter” “Firm Shares” “Common Stock” Agreement “Option Shares” “Securities.” 1. Registration Statement and Prospectus “Commission” “Securities Act” “Act” “Rules and Regulations” “Rule 430B Information” “Registration Statement.” “Original Registration Statement.” Rule 462(b) Registration] [CCG Investor Relations Athan Dounis, Account Manager Tel: +1-646-213-1916 Email: athan.dounis@ccgir.com Orient Paper, Inc. Winston Yen, CFO Phone: +1-562-818-3817 (Los Angeles) info@orientalpapercorporation.com Email: Orient Paper Announces Pricing of Public Offering of Common Stock BAODING, Hebei, China – March 31, 2010, Orient Paper, Inc. Orient Paper, Inc. has granted the underwriter a 45-day option to purchase up to an additional 450,000] [Item 1.01. Entry into a Material Definitive Agreement. On March 31, 2010, Orient Paper, Inc., a Nevada corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Roth Capital Partners LLC (the “Underwriter”) for the sale of 3,000,000 shares of the Company’s common stock, par value $0.001 per share, for a purchase price of $7.796 per share (net]
[TABLE OF CONTENTS PART I Item 1. Business. 1-4] [EX-23.1 2 v179305_ex23-1.htm] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors of Kandi Technologies, Corp. WEINBERG & COMPANY, P.A. Certified Public Accountants Boca Raton, Florida March 31, 2010 EX-23.2 4 v179305_ex23-2.htm] [I, Hu Xiaoming, certify that: 1. I have reviewed this annual report on Form 10-K of Kandi Technologies, Corp. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made,] [I, Zhu Xiaoying, certify that: 1. I have reviewed this annual report on Form 10-K of Kandi Technologies, Corp. 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Hu Xiaoming President and Chief Executive Officer Zhu Xiaoying Chief Financial Officer March 31, 2010 EX-32.1 7 v179305_ex32-1.htm]
[The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting offers to buy these securities in any state where the offer or sale is not permitted. Registration No. 333-163340 SUBJECT TO COMPLETION, DATED MARCH 31,]